2024 年年度股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码： 301097 证券简称：天益医疗 公告编号：2025-035 宁波天益医疗器械股份有限公司 特别提示： 1、本次股东会无增加、变更、否决提案的情况； 2、本次股东会以现场投票和网络投票相结合的方式召开； 3、本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开情况： 1、会议召集人：宁波天益医疗器械股份有限公司董事会 2、召开方式：本次股东会采用现场投票与网络投票相结合的方式召开 3、会议召开时间 （1）现场会议时间：2025 年 5 月 6 日 13:00 （2）网络投票时间：2025 年 5 月 6 日 ① 通过深圳证券交易所交易系统进行投票的具体时间为：2025 年 5 月 6 日 9:15-9:25，9:30-11:30 和 13:00-15:00； ② 通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 5 月 6 日 9:15 至 2025 年 5 月 6 日 15:00 期间的任意时间。 4、现场会议召开地点：浙江省宁波市东钱湖旅游度假区 ...

证券代码： 301097 证券简称：天益医疗 公告编号：2025-034 宁波天益医疗器械股份有限公司 关于公司新产品取得产品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 宁波天益医疗器械股份有限公司（以下简称"公司"）于近日收到浙江省药 品监督管理局颁发的《医疗器械注册证》，具体情况如下： 一、产品注册证具体情况 | 序号 | 产品名称 | 注册证编号 | 注册 类别 | | | 注册证有效期 | | | 适用范围 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 一次性使用肠内 | 浙械注准 | II | | | | | | 产品与肠营养器、 经鼻肠营养导管、 | | | | | | | | | | | 经皮肠营养导管 | | | | | | 2025 | 年 4 | 月 | 27 | 日至 | | | | 营养注射器 | 20252141312 | | | 年 | | 月 | 日 | 等营养管路配套 | | | | | | 2030 | | 4 | ...

Group 1: Financial Performance - In 2024, the company achieved a revenue of 418.96 million CNY, representing a year-on-year growth of 9.98% [3] - The net profit for 2024 was -0.744 million CNY, indicating a loss compared to the previous year [3] - The company plans to distribute cash dividends of 5.00 CNY per 10 shares, totaling approximately 28.76 million CNY, despite the negative net profit [8] Group 2: Cost and Expense Management - Management expenses increased by 45.39% and sales expenses rose by 31.25% in 2024 due to rapid growth in personnel [3] - R&D expenses surged by 94.47%, reflecting the company's commitment to innovation and development [6] Group 3: Market and Business Strategy - The company has a foreign sales ratio of approximately 38%, with no significant impact from current tariff policies on completed orders [2] - The construction of the Thailand factory is progressing as planned, with an expected operational start in 2026 [3] - The company is focusing on expanding its market presence both domestically and internationally, particularly in South America [5] Group 4: Product Development and Innovation - The company is actively developing new products, including dialysis solutions and CRRT products, to enhance its product portfolio [4] - The company has acquired CRRT business assets and plans to complete a comprehensive business ecosystem within three years [4] Group 5: Industry Outlook - The medical device industry, particularly in blood purification, is expected to grow due to increasing global end-stage renal disease patients and supportive national policies [6] - The company remains optimistic about the future of the industry, citing the essential nature of its products and the relatively low impact of market fluctuations [6]

Group 1 - The company held its 24th meeting of the third board of directors on April 25, 2025, with all 7 directors present, including one via telecommunication [2][4] - The board unanimously approved the proposal regarding the 2025 Q1 report, confirming that the report accurately reflects the company's operational status without any false records or significant omissions [3][5] - The proposal does not require submission to the shareholders' meeting for approval [6] Group 2 - The company also held its 20th meeting of the third supervisory board on April 25, 2025, with all 3 supervisors present [11][13] - The supervisory board unanimously approved the proposal regarding the 2025 Q1 report, affirming that the report is accurate and complies with legal requirements [11][12] - The decision of the supervisory board is legally valid as it met the quorum requirements [11][13]

一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.0827 | 0.0917 | -9.81 | 0.2345 | | 每股净资产（元） | 20.26 | 21.55 | -5.99 | 21.18 | | 每股公积金(元) | 13.44 | 13.46 | -0.15 | 13.38 | | 每股未分配利润(元) | 6.29 | 6.74 | -6.68 | 6.30 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 0.99 | 0.97 | 2.06 | 0.89 | | 净利润(亿元) | 0.05 | 0.05 | 0 | 0.14 | | 净资产收益率(%) | 0.41 | 0.42 | -2.38 | 1.11 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 486.78万股，累计占流通股比： 26.54%，较 ...

第三届监事会第二十次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 证券代码：301097 证券简称：天益医疗 公告编号：2025-032 宁波天益医疗器械股份有限公司 2025 年 4 月 25 日，宁波天益医疗器械股份有限公司（"公司"）第三届监事 会第二十次会议在公司会议室召开。本次会议由陈云俊主持。应出席监事 3 名， 亲自出席监事 3 名。符合《公司章程》规定的法定人数，本次监事会会议决议合 法有效。 二、监事会会议审议情况 经与会监事审议表决，一致通过如下议案： 1、审议通过了《关于<2025年第一季度报告>的议案》 1、第三届监事会第二十次会议决议。 特此公告。 宁波天益医疗器械股份有限公司监事会 2025 年 4 月 25 日 监事会认为：公司 2025 年第一季度报告的内容真实、准确、完整地反映了 公司 2025 年第一季度经营的实际情况，不存在虚假记载、误导性陈述或者重大 遗漏；报告的编制和审核程序符合法律、行政法规的要求，符合中国证监会及深 圳证券交易所的相关规定。 具体内容详见同日在中国证监会指定创 ...

证券代码：301097 证券简称：天益医疗 公告编号：2025-031 宁波天益医疗器械股份有限公司 第三届董事会第二十四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 二、董事会会议审议情况 经与会董事审议表决，一致通过如下议案： 1、审议通过了《关于<2025 年第一季度报告>的议案》 公司董事会在全面审核公司 2025 年第一季度报告后，一致认为：公司 2025 年第一季度报告的内容真实、准确、完整地反映了公司 2025 年第一季度经营的 实际情况，不存在虚假记载、误导性陈述或者重大遗漏；报告的编制和审核程序 符合法律、行政法规的要求，符合中国证监会及深圳证券交易所的相关规定，同 意对外报出。 表决结果：7 票同意、0 票反对、0 票弃权，0 票回避表决。 本议案已经公司董事会审计委员会审议通过。 本议案无需提交公司股东会审议。 一、董事会会议召开情况 宁波天益医疗器械股份有限公司(以下简称"公司")第三届董事会第二十四 次会议通知于 2025 年 4 月 22 日以电话、短信、电子邮件等方式向公司全体董事 发出。会议于 2025 年 4 ...

Financial Performance - The company's revenue for Q1 2025 was ¥98,512,592.70, representing a 1.65% increase compared to ¥96,914,552.27 in the same period last year[5]. - Net profit attributable to shareholders decreased by 9.81% to ¥4,876,118.66 from ¥5,406,482.66 year-on-year[5]. - The net profit after deducting non-recurring gains and losses was -¥520,711.29, a decline of 123.38% from ¥2,227,226.37 in the same period last year[5]. - The basic and diluted earnings per share were both ¥0.0827, down 9.81% from ¥0.0917 in the same period last year[5]. - Net profit for the current period was ¥4,876,118.66, representing a 16.63% increase from ¥4,180,945.30 in the previous period[28]. - The company reported a comprehensive income total of ¥6,999,527.89, compared to ¥3,611,210.76 in the previous period, indicating a significant increase[29]. Cash Flow and Assets - The net cash flow from operating activities surged by 180.78%, reaching ¥44,901,709.05 compared to ¥15,992,014.05 in the previous year[5]. - Cash and cash equivalents rose to ¥589,291,668.04, up from ¥407,228,869.75, representing a significant increase of about 44.66%[23]. - The total current assets increased to ¥937,961,788.83 from ¥922,876,080.02, reflecting a growth of approximately 1.17%[23]. - The total assets amounted to ¥1,845,252,618.05, compared to ¥1,794,790,236.24, indicating an increase of approximately 2.81%[24]. - The total liabilities increased to ¥651,131,505.41 from ¥602,456,107.11, indicating a rise in financial obligations[25]. - The total equity attributable to shareholders reached ¥1,194,121,112.64, slightly up from ¥1,187,121,584.75 in the previous period[25]. Shareholder Activities - The company approved a share repurchase plan with a total amount between RMB 30 million and RMB 60 million, targeting to buy back 600,000 to 1,200,000 shares, representing 1.02% to 2.04% of the total share capital[13]. - As of February 7, 2025, the company completed the repurchase of 1,427,400 shares at a total cost of RMB 57,641,335.95, accounting for 2.42% of the current total share capital[14]. - The highest share repurchase price was RMB 42.80 per share, while the lowest was RMB 32.71 per share during the buyback period[14]. - The share repurchase period is set from February 8, 2024, to February 7, 2025, following the board's approval[13]. Investments and Acquisitions - The company plans to acquire CRRT filter business assets from BELLCO S.R.L. for an estimated price of €11.99 million, with the transaction yet to be completed[15]. - The company agreed to invest RMB 60 million in a related party, acquiring a 20.87% stake in Ningbo Tianhuiyi Enterprise Management Co., Ltd[16]. - The company and its subsidiary completed the acquisition of CRRT business from Nikkiso Co., Ltd for €43.54 million in February 2025[16]. Research and Development - The increase in sales personnel and R&D staff contributed to higher sales and R&D expenses, impacting net profit[8]. - Research and development expenses rose to ¥11,762,426.61, up from ¥10,309,491.39 in the previous period, reflecting a focus on innovation[27]. - The company is actively expanding its product portfolio with ongoing development and registration of various medical devices[19]. - The company is in the process of registering several new medical devices, including a blood purification device and a continuous blood purification pipeline, currently under review[21]. - The company has multiple new products in the pipeline, with expected approvals for various medical devices extending into 2030[20]. Inventory and Operating Costs - The company reported a significant increase in inventory, with current inventory at ¥85,709,970.06, slightly down from ¥86,799,967.45, indicating a stable inventory management strategy[23]. - Total operating costs increased to ¥98,982,139.54, up 5.00% from ¥93,815,124.46 in the previous period[27].

4月24日，天益医疗今日收盘34.02元，下跌2.52%，最新市净率1.69，总市值20.05亿元。 股东方面，截至2025年4月10日，天益医疗股东户数4030户，较上次增加273户，户均持股市值35.28万 元，户均持股数量2.76万股。 宁波天益医疗器械股份有限公司的主营业务是血液净化及病房护理领域医用高分子耗材等医疗器械的研 发、生产与销售。公司的主要产品是血液净化装置的体外循环血路、一次性使用动静脉穿刺器、血液透 析浓缩液/血液透析干粉、一次性使用一体式吸氧管、喂食器及喂液管。公司陆续获评省级高新技术企 业研究开发中心、国家火炬计划重点高新技术企业、浙江省创新型示范中小企业、浙江省"隐形冠军"企 业等多项荣誉。公司的主要产品血液净化装置的体外循环血路、一次性使用动静脉穿刺器、一次性使用 一体式吸氧管被评为"浙江省优秀工业产品"。 最新一期业绩显示，2024年年报，公司实现营业收入4.19亿元，同比9.98%；净利润-743965.6元，同 比-101.17%，销售毛利率35.88%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)1天益医疗-2695.54-2695.541.6920.05亿 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 宁波天益医疗器械股份有限公司（以下简称"公司"）于2022年4月25日召开第二届董事会第十七次会议 和第二届监事会第七次会议，并于2022年5月16日召开公司2021年年度股东大会，审议通过了《关于使 用部分闲置募集资金及自有资金进行现金管理的议案》，同意公司及子公司在确保不影响募集资金投资 项目建设和公司正常生产经营的前提下，使用不超过人民币40,000万元暂时闲置募集资金及不超过人民 币50,000万元暂时闲置自有资金进行现金管理，使用期限自股东大会审议通过之日起12个月内有效，在 上述额度和期限内，资金可循环滚动使用。具体内容详见公司在创业板信息披露网站巨潮资讯网 （http://www.cninfo.com.cn）披露的《关于使用部分闲置募集资金及自有资金进行现金管理的公告》 （公告编号：2022-007）。 基于现金管理的需要，公司分别在申万宏源证券有限公司宁波分公司、中国建设银行股份有限公司宁波 鄞州分行、招商银行宁波分行文化广场支行开立了募集资金理财 ...